1
|
Anderson RF, Shinde SS, Maroz A, Reynisson J. The reduction potential of the slipped GC base pair in one-electron oxidized duplex DNA. Phys Chem Chem Phys 2020; 22:642-646. [PMID: 31822872 DOI: 10.1039/c9cp05544d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Redox equilibrium between the low potential aniline radical cation and the guanine in the GC base pair of duplex DNA has been established using pulse radiolysis. We relate the measurement of a radical one-electron reduction potential, E0', of 1.01 ± 0.03 V to the perturbation of the GC base pair to accommodate the neutral guanyl radical in an energetically more stable 'slipped' structure. The formation of the 'slipped' structure is exothermic by -11.4 kcal mol-1 as calculated by DFT, which is inline with our experimental results.
Collapse
Affiliation(s)
- Robert F Anderson
- Auckland Cancer Society Research Centre, University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New Zealand.
| | | | | | | |
Collapse
|
2
|
Anderson RF, Yadav P, Patel D, Reynisson J, Tipparaju SR, Guise CP, Patterson AV, Denny WA, Maroz A, Shinde SS, Hay MP. Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000. Org Biomol Chem 2014; 12:3386-92. [PMID: 24737463 DOI: 10.1039/c4ob00236a] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The radical species underlying the activity of the bioreductive anticancer prodrug, SN30000, have been identified by electron paramagnetic resonance and pulse radiolysis techniques. Spin-trapping experiments indicate both an aryl-type radical and an oxidising radical, trapped as a carbon-centred radical, are formed from the protonated radical anion of SN30000. The carbon-centred radical, produced upon the one-electron oxidation of the 2-electron reduced metabolite of SN30000, oxidises 2-deoxyribose, a model for the site of damage on DNA which leads to double strand breaks. Calculations using density functional theory support the assignments made.
Collapse
Affiliation(s)
- Robert F Anderson
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Maroz A, Stachorski L, Emmrich S, Reinhardt K, Xu J, Shao Z, Käbler S, Dertmann T, Hitzler J, Roberts I, Vyas P, Juban G, Hennig C, Hansen G, Li Z, Orkin S, Reinhardt D, Klusmann JH. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia 2013; 28:1259-70. [PMID: 24336126 PMCID: PMC4047213 DOI: 10.1038/leu.2013.373] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 12/01/2013] [Accepted: 12/03/2013] [Indexed: 02/06/2023]
Abstract
Transient leukemia (TL) is evident in 5–10% of all neonates with Down syndrome (DS) and associated with N-terminal truncating GATA1-mutations (GATA1s). Here we report that TL cell clones generate abundant eosinophils in a substantial fraction of patients. Sorted eosinophils from patients with TL and eosinophilia carried the same GATA1s-mutation as sorted TL-blasts, consistent with their clonal origin. TL-blasts exhibited a genetic program characteristic of eosinophils and differentiated along the eosinophil lineage in vitro. Similarly, ectopic expression of Gata1s, but not Gata1, in wild-type CD34+-hematopoietic stem and progenitor cells induced hyperproliferation of eosinophil promyelocytes in vitro. While GATA1s retained the function of GATA1 to induce eosinophil genes by occupying their promoter regions, GATA1s was impaired in its ability to repress oncogenic MYC and the pro-proliferative E2F transcription network. ChIP-seq indicated reduced GATA1s occupancy at the MYC promoter. Knockdown of MYC, or the obligate E2F-cooperation partner DP1, rescued the GATA1s-induced hyperproliferative phenotype. In agreement, terminal eosinophil maturation was blocked in Gata1Δe2 knockin mice, exclusively expressing Gata1s, leading to accumulation of eosinophil precursors in blood and bone marrow. These data suggest a direct relationship between the N-terminal truncating mutations of GATA1 and clonal eosinophilia in DS patients.
Collapse
Affiliation(s)
- A Maroz
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - L Stachorski
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - S Emmrich
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - K Reinhardt
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - J Xu
- 1] Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA [2] Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA [3] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Z Shao
- 1] Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA [2] Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA [3] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S Käbler
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - T Dertmann
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - J Hitzler
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - I Roberts
- Oxford University Department of Paediatrics, Childrens Hospital and Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, UK
| | - P Vyas
- 1] MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK [2] Department of Haematology, Oxford University Hospital, NHS Trust, Oxford, UK
| | - G Juban
- 1] MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK [2] Department of Haematology, Oxford University Hospital, NHS Trust, Oxford, UK
| | - C Hennig
- Department of Pediatric Pneumology, Hannover Medical School, Hannover, Germany
| | - G Hansen
- Department of Pediatric Pneumology, Hannover Medical School, Hannover, Germany
| | - Z Li
- Division of Genetics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - S Orkin
- 1] Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA [2] Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA [3] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - D Reinhardt
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - J-H Klusmann
- Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
4
|
Dertmann T, Maroz A, Klusmann JH. Finding the molecular basis for developmental-stage specific differences in hematopoietic stem and progenitor cells. Klin Padiatr 2013. [DOI: 10.1055/s-0033-1343636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Kelso GF, Maroz A, Cochemé HM, Logan A, Prime TA, Peskin AV, Winterbourn CC, James AM, Ross MF, Brooker S, Porteous CM, Anderson RF, Murphy MP, Smith RAJ. A mitochondria-targeted macrocyclic Mn(II) superoxide dismutase mimetic. ACTA ACUST UNITED AC 2013; 19:1237-46. [PMID: 23102218 DOI: 10.1016/j.chembiol.2012.08.005] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Revised: 07/27/2012] [Accepted: 08/04/2012] [Indexed: 12/14/2022]
Abstract
Superoxide (O(2)(·-)) is the proximal mitochondrial reactive oxygen species underlying pathology and redox signaling. This central role prioritizes development of a mitochondria-targeted reagent selective for controlling O(2)(·-). We have conjugated a mitochondria-targeting triphenylphosphonium (TPP) cation to a O(2)(·-)-selective pentaaza macrocyclic Mn(II) superoxide dismutase (SOD) mimetic to make MitoSOD, a mitochondria-targeted SOD mimetic. MitoSOD showed rapid and extensive membrane potential-dependent uptake into mitochondria without loss of Mn and retained SOD activity. Pulse radiolysis measurements confirmed that MitoSOD was a very effective catalytic SOD mimetic. MitoSOD also catalyzes the ascorbate-dependent reduction of O(2)(·-). The combination of mitochondrial uptake and O(2)(·-) scavenging by MitoSOD decreased inactivation of the matrix enzyme aconitase caused by O(2)(·-). MitoSOD is an effective mitochondria-targeted macrocyclic SOD mimetic that selectively protects mitochondria from O(2)(·-) damage.
Collapse
Affiliation(s)
- Geoffrey F Kelso
- Centre for Green Chemistry, Monash University, Victoria 3800, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Maroz A, Hennig C, Van Handel B, Mikkola H, Reinhardt D, Klusmann JH. Formation of atypical, hyperproliferating eosinophilic precursors by overexpression of GATA1s. Klin Padiatr 2012. [DOI: 10.1055/s-0032-1310470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Kettle AJ, Maroz A, Woodroffe G, Winterbourn CC, Anderson RF. Spectral and kinetic evidence for reaction of superoxide with compound I of myeloperoxidase. Free Radic Biol Med 2011; 51:2190-4. [PMID: 22002086 DOI: 10.1016/j.freeradbiomed.2011.09.019] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Revised: 09/15/2011] [Accepted: 09/17/2011] [Indexed: 12/01/2022]
Abstract
Superoxide and myeloperoxidase (MPO) are essential for the oxidative killing of bacteria by neutrophils. Previously, we developed a kinetic model to demonstrate that within the confines of neutrophil phagosomes, superoxide should react exclusively with MPO and be converted to hypochlorous acid. The model consists of all known reactions and rate constants for reactions of superoxide, hydrogen peroxide, and chloride ions with MPO, except for the reaction of superoxide with compound I, which could only be estimated. Compound I is a transitory redox intermediate of MPO that is responsible for oxidizing chloride ions to hypochlorous acid. To tackle the challenge of observing the reaction between two transient species, we combined stopped-flow spectrophotometry with pulse radiolysis. Using this technique, we directly observed the reduction of compound I by superoxide. The rate constant for the reaction was determined to be 5.6±0.3×10(6)M(-1)s(-1). This value establishes superoxide as one of the best substrates for compound I. Based on this value, the rate constant for reduction of compound II by superoxide was determined to be 1.2±0.1×10(6)M(-1)s(-1). Within phagosomes, the reduction of compound I by superoxide will compete with the oxidation of chloride ions so that the relative concentrations of these two substrates will affect the yield of hypochlorous acid. Characterization of this reaction confirms that superoxide is a physiological substrate for MPO and that their interactions are central to an important host defense mechanism.
Collapse
Affiliation(s)
- Anthony J Kettle
- Free Radical Research Group, Department of Pathology, University of Otago at Christchurch, Christchurch, New Zealand.
| | | | | | | | | |
Collapse
|
8
|
Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2011; 11:740-51. [PMID: 22147748 DOI: 10.1158/1535-7163.mct-11-0634] [Citation(s) in RCA: 140] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP) of bromo-isophosphoramide mustard currently undergoing clinical evaluation. Here, we describe broad-spectrum activity, hypoxia-selective activation, and mechanism of action of TH-302. The concentration and time dependence of TH-302 activation was examined as a function of oxygen concentration, with reference to the prototypic HAP tirapazamine, and showed superior oxygen inhibition of cytotoxicity and much improved dose potency relative to tirapazamine. Enhanced TH-302 cytotoxicity under hypoxia was observed across 32 human cancer cell lines. One-electron reductive enzyme dependence was confirmed using cells overexpressing human NADPH:cytochrome P450 oxidoreductase and radiolytic reduction established the single-electron stoichiometry of TH-302 fragmentation (activation). Examining downstream effects of TH-302 activity, we observed hypoxia-dependent induction of γH2AX phosphorylation, DNA cross-linking, and cell-cycle arrest. We used Chinese hamster ovary cell-based DNA repair mutant cell lines and established that lines deficient in homology-dependent repair, but not lines deficient in base excision, nucleotide excision, or nonhomologous end-joining repair, exhibited marked sensitivity to TH-302 under hypoxia. Consistent with this finding, enhanced sensitivity to TH-302 was also observed in lines deficient in BRCA1, BRCA2, and FANCA. Finally, we characterized TH-302 activity in the three-dimensional tumor spheroid and multicellular layer models. TH-302 showed much enhanced potency in H460 spheroids compared with H460 monolayer cells under normoxia. Multicellular layers composed of mixtures of parental HCT116 cells and HCT116 cells engineered to express an oxygen-insensitive bacterial nitroreductase showed that TH-302 exhibits a significant bystander effect.
Collapse
Affiliation(s)
- Fanying Meng
- Threshold Pharmaceuticals, 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Smaill JB, Jaiswal J, Abbattista M, Lu GL, Anderson RF, Ashoorzadeh A, Denny WA, Donate F, Hsu HL, Lee HH, Maroz A, Mehta S, Pruijn A, Puryer M, Syddall SP, Thompson A, van Leeuwen W, Wilson WR, Jamieson S, Patterson AV. Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-a247] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Hypoxia occurs in most human tumors and is associated with disease progression, treatment resistance and poor patient outcome. We have developed the hypoxia-activated prodrug SN29966, designed to release the irreversible pan-HER inhibitor SN29926, following one-electron reduction by hypoxic cells (Smaill et al, Mol Cancer Ther., 2009; 8(12 Suppl), C46). Pharmacokinetic (PK) studies in nude mice bearing A431 tumor xenografts indicated SN29966 has a long tumor half-life (>3 days) and releases SN29926 in tumors. SN29966 demonstrated single agent activity in nude mice bearing A431 and SKOV3 xenografts, inducing striking tumor regressions in both models (Patterson et al, Mol Cancer Ther., 2009; 8(12 Suppl), B76). PR509 and PR610, clinical candidates developed from SN29966, are currently undergoing comparative evaluation with Phase I trials anticipated in early 2012.
The single-agent antitumor activity of SN29966 is arguably counter-intuitive given that it is designed to target hypoxic cells within tumors. This activity may arise from a number of contributing mechanisms including; (i) bioactivity of the unreduced prodrug; (ii) local redistribution of released inhibitor in the tumor; (iii) liver metabolism and circulating inhibitor and (iv) a long tumor half-life allowing for targeting of both chronic and cycling hypoxia. To critically assess the relative contribution of each to the mechanism of action of SN29966 we performed a number of studies. We prepared SN31950, a prodrug of SN29926 designed to be incapable of one-electron fragmentation. In target modulation and anti-proliferative assays SN31950 showed no hypoxia-dependent activity. The murine A431 tumor PK of SN29966 and SN31950 demonstrated that at an equimolar dose (20 μmol/kg, ip), both prodrugs gave comparable tumor exposures (AUC0–72h: SN31950, 50 μmol*h/kg; SN29966, 57 μmol*h/kg). In contrast, the tumor exposure of SN29926 released from each prodrug differed by 40-fold (AUC0–72h: SN29926 from SN31950, 0.3 μmol*h/kg; SN29926 from SN29966, 12 μmol*h/kg). Plasma exposure of each prodrug was comparable, as were levels of SN29926 in plasma (presumed mainly due to hepatic prodrug metabolism). Consistent with the observed lack of inhibitor release in A431 tumors, SN31950 was inactive against A431 tumors in growth delay assays. To confirm the hypoxia-dependent nature of SN29966 inhibitor release in A431 tumors we re-oxygenated tumors in mice breathing 100% oxygen at 2.5 atm in a hyperbaric chamber. Accordingly, mice showed a marked reduction (56%, p<0.001) in the concentration of released inhibitor in tumor relative to air breathing controls, indicating SN29966 tumor metabolism is hypoxia-dependent. Conversely, post-mortem anoxia (2 h, 37 °C) in mice 24 hours after SN29966 administration doubled the concentration of released inhibitor in tumor, indicating SN29966 is bioavailable for metabolism to release inhibitor as de novo hypoxia arises. Collectively the data support the conclusion that the single-agent activity of SN29966 results primarily from hypoxia-dependent tumor metabolism and inhibitor release. Inhibitor bystander effect and exploitation of both chronic and cycling hypoxia, thereby increasing the target cell population, are likely to play important roles. Liver metabolism, circulating inhibitor and activity of unreduced prodrug appear to be less important.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A247.
Collapse
Affiliation(s)
| | | | | | - Guo-Liang Lu
- 1The University of Auckland, Auckland, New Zealand
| | | | | | | | | | | | - Ho H. Lee
- 1The University of Auckland, Auckland, New Zealand
| | - Andrej Maroz
- 1The University of Auckland, Auckland, New Zealand
| | - Sunali Mehta
- 1The University of Auckland, Auckland, New Zealand
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Maroz A, Hennig C, Reinhardt D, Klusmann JH. GATA1s exerts fetal stage-specific oncogenic effects in hematopoietic stem and progenitor cells. Klin Padiatr 2011. [DOI: 10.1055/s-0031-1277089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc 2010; 132:2591-9. [PMID: 20141134 DOI: 10.1021/ja908689f] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The mechanism by which the 1,2,4-benzotriazine 1,4-dioxide (BTO) class of bioreductive hypoxia-selective prodrugs (HSPs) form reactive radicals that kill cancer cells has been investigated by steady-state radiolysis, pulse radiolysis (PR), electron paramagnetic resonance (EPR), and density functional theory (DFT) calculations. Tirapazamine (TPZ, 3-amino BTO, 1) and a series of 3-substituted analogues, -H (2), -methyl (3), -ethyl (4), -methoxy (5), -ethoxymethoxy (6), and -phenyl (7), were reduced in aqueous solution under anaerobic steady-state radiolysis conditions, and their radicals were found to remove the substrates by short chain reactions of different lengths in the presence of formate ions. Multiple carbon-centered radical intermediates, produced upon anaerobic incubation of the compounds with cytochrome P(450) reductase enriched microsomes, were trapped by N-tert-butyl-alpha-phenylnitrone and observed using EPR. The highly oxidizing oxymethyl radical, from compound 5, was identified, and experimental spectra obtained for compounds 1, 2, 3, and 7 were well simulated after the inclusion of aryl radicals. The identification of a range of oxidizing radicals in the metabolism of the BTO compounds gives a new insight into the mechanism by which these HSPs can cause a wide variety of damage to biological targets such as DNA.
Collapse
Affiliation(s)
- Sujata S Shinde
- Department of Chemistry and Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | | | | | | | | | | |
Collapse
|
12
|
Lu GL, Smaill JB, Abbattisia M, Anderson RF, Ashoorzadeh A, Denny WA, Doñate F, Hsu A, Jaiswal J, Jamieson S, Lee HH, Maroz A, Mehta S, Pruijn A, Syddall SP, Thompson A, van Leeuwen W, Wilson WR, Patterson AV. Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-lb-297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Reversible HER1 (EGFR) inhibitors erlotinib and gefitinib are approved for use in non-small cell lung cancer (NSCLC), particularly demonstrating activity against tumors expressing mutant forms of HER1. Unfortunately, relapse invariably occurs in this patient population, with approximately half of patients having acquired an additional T790M mutation in HER1. Irreversible pan-HER inhibitors (BIBW2992, PF00299804) are under clinical evaluation in the context of NSCLC that has relapsed post-erlotinib/gefitinib treatment. However it is currently unclear whether these agents possess the therapeutic index in man necessary to gain approval in this setting (Regales et al., J. Clin. Invest. 2009, 119:3000-10), prompting the development of HER1T790M mutant-selective irreversible inhibitors (Zhou et al., Nature. 2009, 462: 1070-74).
Hypoxia occurs in most human tumors and is associated with disease progression, resistance to conventional therapies and poor patient outcome. It can however be considered as an exploitable physiological target, as it supports tumor-selective bioreduction of prodrugs. We have developed hypoxia-activated prodrugs of irreversible pan-HER inhibitors as a strategy to broaden their therapeutic index. SN29966 is a prototype nitromethylaryl quaternary (NMQ) ammonium salt prodrug of an irreversible pan-HER inhibitor (SN29926), with masked cellular activity. Radiolytic reduction of SN29966 demonstrated fragmentation of the one-electron adduct to release SN29926 [kfrag 130 ± 10 s-1], and hypoxia-selective metabolism to SN29926 has been confirmed in all cell lines tested.
SN32807 is the lead prodrug of this series, releasing the irreversible pan-HER inhibitor SN32793 in a hypoxia-dependent manner. In a panel of HER1/HER1T790M/HER2-expressing cell lines SN32807 showed hypoxia-dependent inhibition of proliferation (hypoxic/oxic IC50 ratios of 60, 11 and 20 in A431, H1975 and SKOV3 cells, respectively), a property SN32793 lacked (IC50 ratios 0.8-1.6). Tumor growth delay experiments (NIH-III nude mice) in large (500 mm3) HER1T790M-expressing H1975 tumor xenografts showed BIBW2992 (20 mg/kg, p.o. daily) failed to control tumor growth (i.e. progressive disease), with only a modest Tumor Growth Delay value of 35% [TGD % = [(T-C)/C]x100 where T and C are time to 4-fold increase in tumor volume from treatment day-1 for treated and control tumors, respectively]. In contrast, single-agent SN32807 (88 mg/kg; ip, q3dx8) demonstrated complete tumor responses in all animals during the treatment period (TGD value 246%; P<0.0005 vs controls; P<0.0005 vs BIBW-2992; log-rank test). Collectively the data indicates that SN32807 possesses a much improved therapeutic index relative to existing HER-family inhibitors, demonstrating marked activity against a HER1T790M-expressing erlotinib, gefitinib and BIBW2992 resistant tumor xenograft model.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-297.
Collapse
Affiliation(s)
- Guo-Liang Lu
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Jeff B. Smaill
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Maria Abbattisia
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Robert F. Anderson
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Amir Ashoorzadeh
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - William A. Denny
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | | | - Annie Hsu
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Jagdish Jaiswal
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Stephen Jamieson
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Ho H. Lee
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Andrej Maroz
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Sunali Mehta
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Alison Pruijn
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Sophie P. Syddall
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Aaron Thompson
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Wouter van Leeuwen
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - William R. Wilson
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| | - Adam V. Patterson
- 1Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
13
|
Maroz A, Shinde SS, Franzblau SG, Ma Z, Denny WA, Palmer BD, Anderson RF. Release of nitrite from the antitubercular nitroimidazoledrug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent. Org Biomol Chem 2010; 8:413-8. [DOI: 10.1039/b915877d] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Smaill JB, Lu GL, van Leeuwen W, Abbattista M, Anderson RF, Denny WA, Doñate F, Jaswail J, Maroz A, Puryer M, Syddall SP, Wilson WR, Patterson AV. Abstract C46: Design and identification of the novel hypoxia-activated irreversible pan-HER inhibitor SN29966. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-c46] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Several irreversible pan-HER inhibitors (HKI-272, BIBW-2992, PF299) are under development and demonstrate encouraging activity against erlotinib resistant non-small cell lung cancer expressing mutant forms of HER1. However, dose limiting toxicities mirror that of erlotinib and are attributed to inhibition of HER1 in gastrointestinal and skin tissues. To introduce additional tumor selectivity to irreversible pan-HER inhibitors and thereby broaden their therapeutic index, we have sought to utilise tumor hypoxia as a physiological target that supports tumor-selective bioreduction. To achieve this we have developed a series of hypoxia-activated prodrugs of the known irreversible pan-HER inhibitor SN29926.
Five nitromethylaryl quaternary ammonium bromide (NMQ) prodrugs were synthesised by quaternizing the tertiary amine of SN29926 with five nitroheterocyclic alpha-methyl bromides. Three further quaternary salts were prepared as Chemical-Biology Tools (CBTs) designed as controls to probe aspects of the mechanism of action of the NMQ prodrugs. The NMQ prodrugs and CBTs were compared, relative to SN29926, in a range of assays to identify a lead compound that (i) is deactivated under oxic conditions with respect to A431 cellular HER1 target modulation and proliferation, (ii) efficiently fragments following one-electron reduction in an oxygen inhibited manner to release the irreversible pan-HER inhibitor, (iii) displays increased anti-proliferative activity against A431 cells under hypoxia.
All of the NMQ/CBT prodrugs were successfully deactivated with respect to inhibition of A431 HER1 autophosphorylation (62- to 201-fold) and proliferation under oxic conditions (12- to 294-fold). Pulse and steady-state radiolysis under nitrogen determined their one-electron reduction potentials (−388 to −493 mV) and demonstrated that only two of the NMQ prodrugs (SN29965, SN29966) efficiently fragment following one-electron reduction (first-order rate constants of 90 and 130 s−1, respectively). SN29966 alone demonstrated significant anti-proliferative activity against A431 cells under hypoxia (hypoxic/oxic IC50 ratio 38). Preliminary growth delay screening of SN29966 and the CBTs in advanced A431 xenografts (∼600 mm3; hypoxic fraction of 32% ± 13%) demonstrated that the CBTs lacked efficacy, while SN29966 induced tumor regressions, with greater than 30 days tumor control using a well tolerated three-dose schedule (133 umol/kg/dose, q4dx3). In summary, prodrug SN29966 is deactivated relative to the parent inhibitor, efficiently fragments following one-electron reduction, is selective against hypoxic A431 cells and has remarkable single-agent activity against hypoxic A431 xenografts using a conservative treatment schedule. We therefore identify SN29966 as a “first-in-class” hypoxia-activated irreversible pan-HER inhibitor that has significant clinical potential.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C46.
Collapse
|
15
|
Shinde SS, Maroz A, Hay MP, Anderson RF. One-electron reduction potential of the neutral guanyl radical in the GC base pair of duplex DNA. J Am Chem Soc 2009; 131:5203-7. [PMID: 19320486 DOI: 10.1021/ja8087339] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The one-electron oxidation of guanine in the GC base pair of DNA has been investigated using pulse radiolysis combined with DFT calculations. Reaction of benzotriazinyl radicals with DNA results in the formation of the neutral guanyl radical and redox equilibria. The one-electron reduction potential, E(7), of the neutral guanyl radical in the GC base pair is determined for the first time as 1.22 +/- 0.02 V, from both absorption and kinetic data.
Collapse
Affiliation(s)
- Sujata S Shinde
- Department of Chemistry and Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | | | | | | |
Collapse
|
16
|
Maroz A, Anderson RF, Smith RAJ, Murphy MP. Reactivity of ubiquinone and ubiquinol with superoxide and the hydroperoxyl radical: implications for in vivo antioxidant activity. Free Radic Biol Med 2009; 46:105-9. [PMID: 18977291 DOI: 10.1016/j.freeradbiomed.2008.09.033] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 09/24/2008] [Accepted: 09/25/2008] [Indexed: 11/28/2022]
Abstract
Endogenous ubiquinones (UQ) such as coenzyme Q(10) are essential electron carriers in the mitochondrial respiratory chain, and the reduced ubiquinol form (UQH(2)) is a chain-breaking antioxidant, decreasing oxidative damage caused by lipid peroxidation within mitochondria. Consequently, exogenous UQ are used as therapies to decrease mitochondrial oxidative damage. The proximal radical produced during mitochondrial oxidative stress is superoxide (O(2)(.-)) and the reaction between UQ and O(2)(.-) to form the ubisemiquinone radical anion (UQ(.-)) may also be important for the scavenging of O(2)(.-) by exogenous UQ. The situation in vivo is that many UQ are predominantly located in the hydrophobic membrane core, from which O(2)(.-) will be excluded but its conjugate acid, HOO(.), can enter. The reactivity of UQ or UQH(2) with HOO(.) has not been reported previously. Here a pulse radiolysis study on the reactions between UQ/UQH(2) and O(2)(.-)/HOO(.) in water and in solvent systems mimicking the surface and core of biological membranes has been undertaken. O(2)(.-) reacts very rapidly with UQ, suggesting that this may contribute to the scavenging of O(2)(.-) in vivo. In contrast, UQH(2) reacts relatively slowly with HOO(.), but rapidly with other oxygen- and carbon-centered radicals, indicating that the antioxidant role of UQH(2) is mainly in preventing lipid peroxidation.
Collapse
Affiliation(s)
- Andrej Maroz
- Department of Chemistry, The University of Auckland, New Zealand
| | | | | | | |
Collapse
|
17
|
Maroz A, Kelso GF, Smith RAJ, Ware DC, Anderson RF. Pulse Radiolysis Investigation on the Mechanism of the Catalytic Action of Mn(II)−Pentaazamacrocycle Compounds as Superoxide Dismutase Mimetics. J Phys Chem A 2008; 112:4929-35. [DOI: 10.1021/jp800690u] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Andrej Maroz
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Centre for Green Chemistry, Monash University, P.O. Box 75, Clayton, Victoria 3800, Australia
- Department of Chemistry, University of Otago, Box 56, Dunedin 9054, New Zealand
| | - Geoffrey F. Kelso
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Centre for Green Chemistry, Monash University, P.O. Box 75, Clayton, Victoria 3800, Australia
- Department of Chemistry, University of Otago, Box 56, Dunedin 9054, New Zealand
| | - Robin A. J. Smith
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Centre for Green Chemistry, Monash University, P.O. Box 75, Clayton, Victoria 3800, Australia
- Department of Chemistry, University of Otago, Box 56, Dunedin 9054, New Zealand
| | - David C. Ware
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Centre for Green Chemistry, Monash University, P.O. Box 75, Clayton, Victoria 3800, Australia
- Department of Chemistry, University of Otago, Box 56, Dunedin 9054, New Zealand
| | - Robert F. Anderson
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Centre for Green Chemistry, Monash University, P.O. Box 75, Clayton, Victoria 3800, Australia
- Department of Chemistry, University of Otago, Box 56, Dunedin 9054, New Zealand
| |
Collapse
|
18
|
Anderson RF, Shinde SS, Maroz A, Boyd M, Palmer BD, Denny WA. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Org Biomol Chem 2008; 6:1973-80. [PMID: 18480913 DOI: 10.1039/b801859f] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The reduction chemistry of the new anti-tuberculosis drug PA-824, together with a more water-soluble analogue, have been investigated using pulse and steady-state radiolysis in aqueous solution. Stepwise reduction of these nitroimidazo-dihydrooxazine compounds through electron transfer from the CO(2) (-) species revealed that, unlike related nitroimidazoles, 2-electron addition resulted in the reduction of the imidazole ring in preference to the nitro group. In mildly acidic solution a nitrodihydroimidazo intermediate was formed, which was reduced further to the amine product. In both alkaline and neutral solution, an intermediate produced on 2-electron reduction was resistant to further reduction and reverted to parent compound on extraction or mass spectrometric analysis of the solution. The unusual reduction chemistry of these nitroimidazole compounds, exhibiting ring over nitro group reduction, is associated with alkoxy substitution in the 2-position of a 4-nitroimidazole. The unique properties of the intermediates formed on the reduction of PA-824 need to be considered as playing a possible role in its bactericidal action.
Collapse
Affiliation(s)
- Robert F Anderson
- Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
| | | | | | | | | | | |
Collapse
|
19
|
Abstract
The selenite radical, SeO3-, has been found to selectively produce the cytosyl radical upon one-electron oxidation of duplex DNA. This is at first a surprising result as SeO3- can only oxidize guanine of the DNA bases, implying that the transiently formed guanyl radical cation must transpose into the neutral cytosyl radical with loss of a proton. Back oxidation to produce the neutral guanyl radical, in competition with another fixation reaction, is observed.
Collapse
Affiliation(s)
- Robert F Anderson
- Department of Chemistry, The University of Auckland, Auckland 1, New Zealand.
| | | | | |
Collapse
|
20
|
Brede O, Maroz A, Hermann R, Naumov S. Ionization of Cyclic Aromatic Amines by Free Electron Transfer: Products Are Governed by Molecule Flexibility. J Phys Chem A 2005; 109:8081-7. [PMID: 16834193 DOI: 10.1021/jp053172x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The bimolecular electron transfer from secondary aromatic amines to parent radical cations of nonpolar solvents such as alkanes and alkyl chlorides results in the synchronous formation of amine radical cations as well as aminyl radicals, in comparable amounts. If as for cyclic aromatic amines (c-Ar(2)NH) the intramolecular bending motion around the amine group is restricted in varying degrees (acridane, phenothiazine) or completely prevented (carbazole), then this picture is modified. In the free electron transfer, the completely rigid carbazole yields exclusively amine radical cations. Acridane exhibits preferred radical cations, but phenothiazine with the more flexible six-membered ring involving sulfur as a further heteroatom follows the common two-product rule; see above. The phenomenon is reasoned by a peculiarity in the bimolecular free electron transfer where after diffusional approach the actual electron jump proceeds in the ultrashort time range. Therefore, it reflects femtosecond molecular motions which, in the case of free mobility, continuously pass through different molecule conformers, combined with fluctuation of the electrons of the responsible molecular n-orbitals. The rigid systems, however, do not show this effect because of a nonexistent bending motion.
Collapse
Affiliation(s)
- Ortwin Brede
- Interdisciplinary Group Time-Resolved Spectroscopy, University of Leipzig, Permoserstrasse 15, 04303 Leipzig, Germany.
| | | | | | | |
Collapse
|
21
|
Maroz A, Hermann R, Naumov S, Brede O. Ionization of Aniline and Its N-methyl and N-phenyl Substituted Derivatives by (Free) Electron Transfer to n-butyl Chloride Parent Radical Cations. J Phys Chem A 2005; 109:4690-6. [PMID: 16833809 DOI: 10.1021/jp0503056] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The electron transfer from aniline and its N-methyl as well as N-phenyl substituted derivatives (N-methylaniline, N,N-dimethylaniline, diphenylamine, triphenylamine) to parent solvent radical cations was studied by electron pulse radiolysis in n-butyl chloride solution. The ionization results in the case of aniline (ArNH2) and the secondary aromatic amines (Ar2NH, Ar(Me)NH) in the synchronous and direct formation of amine radical cations, as well as aminyl radicals, in comparable amounts. Subsequently, ArNH2*+ deprotonates in a delayed reaction with the present nucleophile Cl-, and forms further ArNH*. In contrast, tertiary aromatic amines such as triphenylamine and dimethylaniline yield primarily the corresponding amine radical cations Ar3N*+ or Ar(Me2)N*+, only. The persistent Ar3N*+ forms a charge transfer complex (dimer) with the parent amine molecule, whereas Ar(Me2)N*+ deprotonates to carbon-centered radicals Ar(Me)NCH2*.
Collapse
Affiliation(s)
- Andrej Maroz
- University of Leipzig, Interdisciplinary Group Time-Resolved Spectroscopy, Permoserstrasse 15, D-04303 Leipzig, Germany
| | | | | | | |
Collapse
|